29 results on '"Wu, X.-N."'
Search Results
2. Exploration and Application of Cloud-Network Integration Control Architecture in Industry.
- Author
-
Sun, R Q, Zhang, Y, Liu, L, Qin, D W, Liu, J W, and Wu, X N
- Published
- 2023
- Full Text
- View/download PDF
3. Crystal structure of PDE8A catalytic domain in complex with 22
- Author
-
Wu, X.-N., primary, Zhou, Q., additional, Huang, Y.-D., additional, Li, Z., additional, Wu, Y., additional, and Luo, H.-B., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Crystal structure of PDE8A catalytic domain in complex with 15
- Author
-
Wu, X.-N., primary, Zhou, Q., additional, Huang, Y.-D., additional, Li, Z., additional, Wu, Y., additional, and Luo, H.-B., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Poor medication adherence to bisphosphonates and high self-perception of aging in elderly female patients with osteoporosis
- Author
-
Wu, X., Wei, D., Sun, B., and Wu, X. N.
- Published
- 2016
- Full Text
- View/download PDF
6. Experimental research on shear performance of single bolt joints of bamboo curtain plywood
- Author
-
Tang, G, primary, Wu, X N, additional, Sun, P, additional, and Yang, C T, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Crystal structure of PDE8A catalytic domain in complex with 3a
- Author
-
Huang, Y., primary, Wu, X.-N., additional, Zhou, Q., additional, Wu, Y., additional, and Luo, H.-B., additional
- Published
- 2021
- Full Text
- View/download PDF
8. Crystal structure of PDE8A catalytic domain in complex with 2c
- Author
-
Huang, Y., primary, Wu, X.-N., additional, Zhou, Q., additional, Wu, Y., additional, and Luo, H.-B., additional
- Published
- 2021
- Full Text
- View/download PDF
9. Crystal structure of PDE8A catalytic domain in complex with clofarabine
- Author
-
Huang, Y., primary, Wu, X.-N., additional, Zhou, Q., additional, Wu, Y., additional, and Luo, H.-B., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Inhibition of microRNA-184 reduces H2O2-mediated cardiomyocyte injury via targeting FBXO28.
- Author
-
ZOU, J.-F., WU, X.-N., SHI, R.-H., SUN, Y.-Q., QIN, F.-J., and YANG, Y.-M.
- Abstract
OBJECTIVE: Cardiovascular disease, especially coronary heart disease, is one of the diseases with the highest mortality. A large number of studies have found that microRNAs (miRNAs) are closely related to the occurrence and development of myocardial ischemia. This article mainly focused on the regulation of miR-184 on oxidative stress, inflammation, and apoptosis in myocardial infarction (MI). MATERIALS AND METHODS: MiR-184 inhibitor or negative control (NC) were transfected into H9c2 cells. Then, H9c2 cells were treated with H
2 O2 to construct a cardiomyocyte injury model. H9c2 cells were divided into 4 groups: control group, H2 O2 treatment group, H2 O2 + NC group, and H2 O2 + miR-184 inhibitor group. The oxidative stress of H9c2 cells was observed by the expression levels of SOD, ROS, and MDA in each group. The inflammatory response of H9c2 cells was reflected by the expression of TNF-α, IL-6, and IL-1β detected by ELISA kits. Western blot was used to detect the expression of cleaved Caspase-3, Bcl2, Bax and F-box protein 28 (FBXO28). Quantitative Real Time-Polymerase Chain Reaction (qRTPCR) was utilized to detect miR-184 expression. TdT-mediated dUTP Nick-End Labeling (TUNEL) staining and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay were used to observe the apoptosis and cell viability. The Luciferase reporter experiment was used to prove whether miR-184 could target FBXO28. RESULTS: MiR-184 expression was significantly increased in H2 O2 -induced H9c2 cell injury model. After H9c2 cells were transfected with miR-184 inhibitor to silence miR-184, the levels of ROS and MDA were markedly reduced, while the expression of SOD was greatly increased. At the same time, the expression of inflammatory factors was greatly reduced. Silencing miR-184 also increased Bcl-2 expression, and reduced the expression of cleaved Caspase-3 and Bax. In addition, compared with the H2 O2 + NC group, the number of TUNEL positive cells in the H2 O2 + miR-184 inhibitor group was also significantly reduced, and the cell viability was remarkably increased. The Luciferase reporter experiment proved that FBXO28 is a target gene of miR-184. CONCLUSIONS: MiR-184 expression was increased in H2 O2 -treated H9c2 cells. Inhibition of miR-184 markedly inhibited oxidative stress and inflammation in cardiomyocytes, thereby inhibiting cardiomyocyte apoptosis, through the regulation of FBXO28. [ABSTRACT FROM AUTHOR]- Published
- 2020
11. Three-dimensional honeycomb-like porous carbon derived from corncob for the removal of heavy metals from water by capacitive deionization
- Author
-
Zhang, X. F., primary, Wang, B., additional, Yu, J., additional, Wu, X. N., additional, Zang, Y. H., additional, Gao, H. C., additional, Su, P. C., additional, and Hao, S. Q., additional
- Published
- 2018
- Full Text
- View/download PDF
12. Research on influencing factors of rebound effect of energy consumption -- Analysis based on provincial panel data in China.
- Author
-
Han, Y., Shi, J. H., and Wu, X. N.
- Subjects
ENERGY intensity (Economics) ,PANEL analysis ,ENERGY consumption - Published
- 2016
13. FAMLF is a target of miR-181b in Burkitt lymphoma.
- Author
-
Li, J. G., Ding, Y., Huang, Y. M., Chen, W. L., Pan, L. L., Li, Y., Chen, X. L., Chen, Y., Wang, S. Y., and Wu, X. N.
- Published
- 2017
- Full Text
- View/download PDF
14. Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis.
- Author
-
Wu, X-N, Yang, Z-H, Wang, X-K, Zhang, Y, Wan, H, Song, Y, Chen, X, Shao, J, and Han, J
- Subjects
- *
KINASES , *PHOSPHOTRANSFERASES , *DIMERS , *AMYLOID , *DIMERIZATION - Abstract
Necroptosis is mediated by a signaling complex called necrosome, containing receptor-interacting protein (RIP)1, RIP3, and mixed-lineage kinase domain-like (MLKL). It is known that RIP1 and RIP3 form heterodimeric filamentous scaffold in necrosomes through their RIP homotypic interaction motif (RHIM) domain-mediated oligomerization, but the signaling events based on this scaffold has not been fully addressed. By using inducible dimer systems we found that RIP1-RIP1 interaction is dispensable for necroptosis; RIP1-RIP3 interaction is required for necroptosis signaling, but there is no necroptosis if no additional RIP3 protein is recruited to the RIP1-RIP3 heterodimer, and the interaction with RIP1 promotes the RIP3 to recruit other RIP3; RIP3-RIP3 interaction is required for necroptosis and RIP3-RIP3 dimerization is sufficient to induce necroptosis; and RIP3 dimer-induced necroptosis requires MLKL. We further show that RIP3 oligomer is not more potent than RIP3 dimer in triggering necroptosis, suggesting that RIP3 homo-interaction in the complex, rather than whether RIP3 has formed homo polymer, is important for necroptosis. RIP3 dimerization leads to RIP3 intramolecule autophosphorylation, which is required for the recruitment of MLKL. Interestingly, phosphorylation of one of RIP3 in the dimer is sufficient to induce necroptosis. As RIP1-RIP3 heterodimer itself cannot induce necroptosis, the RIP1-RIP3 heterodimeric amyloid fibril is unlikely to directly propagate necroptosis. We propose that the signaling events after the RIP1-RIP3 amyloid complex assembly are the recruitment of free RIP3 by the RIP3 in the amyloid scaffold followed by autophosphorylation of RIP3 and subsequent recruitment of MLKL by RIP3 to execute necroptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. [Analysis of clinical characteristics and curative effects of 169 patients with bilateral sudden sensorineural hearing loss].
- Author
-
Zhao XH, Wu XN, Wang HR, Bing D, Wang DY, and Wang QJ
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Young Adult, Aged, Adolescent, Child, Treatment Outcome, Prognosis, Hearing Loss, Sudden therapy, Hearing Loss, Sudden diagnosis, Hearing Loss, Sensorineural
- Abstract
Objective: To analyze the clinical characteristics, curative effect related factors and follow-up situation of bilateral sudden sensorineural hearing loss (BSSHL). Methods: The clinical data of 169 patients(338 ears) with BSSHL were retrospectively summarized, and the demographic characteristics, predisposing factors, concomitant symptoms and diseases, and audiological characteristics were statistically described. Additionally, influencing factors of curative effect and prognosis were statistically analyzed. Results: Among the 169 patients, 50.9% (86/169) of patients had at least one incentive, with cold and fatigue being the most common incentives(both 23/169). There were high rates of accompanying symptoms including tinnitus (150/169, 88.8%) and dizziness (100/169, 59.2%). Hypertension(49/169, 29.0%)and diabetes(23/169, 13.6%)were the most common concomitant diseases observed. Most cases exhibited all frequencies involvement, with flat type and total deafness type accounting for 83.1%(281/338 ears). The most common degree of hearing loss was total deafness(86/338 ears), with approximately 60.1%(203/338 ears) of the cases being severe or worse. The total effective rate of treatment was only 29.0%, but it increased to 39.5% for patients with course of disease≤14 days, however, when course of disease>30 days, the effective rate decreased sharply to 3.6%, showing a significant difference between these two groups( χ
2 =13.776,<0.01). Different types of hearing curves showed statistically significant difference in efficiency( χ2 =14.782, P <0.01). Comparing the hearing improvements of 28 BSSHL patients from admission to discharge and from discharge to follow-up, it was found that the hearing improvement of the two groups showed statistically significant difference at the frequencies of L-250 Hz, L-500 Hz, R-125 Hz, R-250 Hz and R-500 Hz( Z value was -2.495, -3.083, -3.970, -3.388 and -3.264 respectively, all P <0.05). The proportion of patients with elevated serum IgE was much higher than that of the normal population. Conclusion: BSSHL patients suffer from serious hearing loss, and many also experience tinnitus and vertigo symptoms. Due to the poor efficiency of treatment, it is better for patients to be treated within 30 days of onset. For patients of hearing loss in the low frequency range, hearing improvement is more significant during hospitalization. And the occurrence of BSSHL may involve an immune mechanism.- Published
- 2024
- Full Text
- View/download PDF
16. [Comparison of the population covered by the 2024 version of the WHO's hepatitis B prevention and treatment guidelines and the Chinese antiviral treatment guidelines].
- Author
-
Wang BQ, Shan S, Kong YY, Wu XN, Zhou JL, Sun YM, Chen SY, Wang H, Xu XQ, Xia S, Jia JD, and You H
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, China epidemiology, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Practice Guidelines as Topic, World Health Organization
- Abstract
Objective: This study aims to compare the antiviral treatment similarities and differences in the population covered by the 2024 version of the World Health Organization's (WHO) hepatitis B prevention and treatment guidelines and the current Chinese hepatitis B prevention and treatment guidelines, so as to explore their impact on the indications for antiviral therapy in Chinese patients with chronic hepatitis B (CHB). Methods: The information of patients with chronic hepatitis B virus infection who did not receive antiviral treatment was collected through the registration database of the China Clinical Research Platform for Hepatitis B Elimination. Descriptive statistics were conducted on the demographic, blood, biochemical, and virological levels of patients according to the treatment recommendations of the two versions of the guidelines. The Mann-Whitney U test and χ2 test were used to compare the differences and proportional distribution of the treatment populations covered by the two guidelines. The χ2 test was used to analyze the coverage rate of different antiviral treatment indications. Results: A total of 21,134 CHB patients without antiviral treatment were enrolled. 69.4% of patients met the 2024 versions of the WHO guidelines' recommendations. 85.0% of patients met the current Chinese hepatitis B prevention and treatment guidelines. The WHO guidelines for antiviral therapy indications were met in younger patients with higher levels of ALT, AST, and APRI scores, as well as greater proportion of patients with higher viral loads (P<0.001). The WHO guidelines recommended a cut-off value of APRI>0.5, which raised the proportion of patients on antiviral therapy from 6.6% to 30.9%. 45.7% of patients met the antiviral indications for HBV DNA >2000 IU/ml with abnormal transaminase (ALT>30 U/L for males and ALT>19 U/L for females). The reduced APRI diagnostic cut-off value and ALT treatment threshold had further increased the treatment coverage rate by 91.6% in patients with chronic HBV infection in line with the 2024 versions of WHO guidelines. Conclusion: The reduction of the APRI diagnostic cut-off value and the ALT treatment threshold, based on the current hepatitis B guidelines of China, will further improve the treatment coverage of CHB patients.
- Published
- 2024
- Full Text
- View/download PDF
17. [Progress in Y-linked hereditary deafness and Y chromosome sequencing].
- Author
-
Wu XN, Guan J, and Wang QJ
- Subjects
- Humans, Y Chromosome, Deafness genetics, Hearing Loss, Sensorineural genetics
- Published
- 2022
- Full Text
- View/download PDF
18. [The effect of pregnant rats exposed to radio frequency electromagnetic field on the hippocampal morphology and nerve growth factor of offspring rats].
- Author
-
Zhang SQY, Du PP, Shu X, Wu HX, Mu YZ, Wu XN, and Zhang Y
- Subjects
- Animals, Female, Hippocampus, Male, Mice, Pregnancy, Rats, Rats, Wistar, Semen, Electromagnetic Fields, Nerve Growth Factor
- Abstract
Objective: To explore the effects of exposure of pregnant rats to radio frequency electromagnetic field on the ultrastructure of hippocampus and the levels of obesity related protein (FTO) and nerve growth factor (NGF) in offspring rats. Methods: In September 2019, 36 healthy 7-week-old Wistar rats were selected, including 24 female rats (150-200 g) and 12 male rats (200-250 g) . The male and female mice were mated in the cage at 2: 1 ratio at 18: 00 every night. The smear results showed that the sperm was positive and the mating was successful. The day was regarded as the 0 day of pregnancy. Pregnant rats were randomly divided into 3 experimental groups and 3 control groups, with 4 rats in each group. The experimental group was exposed to 1 800 MHz, Wi-Fi and 1 800 MHz+Wi-Fi respectively, and the three control groups were exposed to virtual exposure. 12 hours a day for 21 days in three batches. After the end of exposure, the offspring of each group were raised for 7 weeks. The ultrastructural changes of the hippocampus were observed by transmission electron microscopy, the FTO level in the hippocampus was determined by Western blot, and the NGF level in the brain tissue was determined by ELISA. Results: Transmission electron microscopy showed that the nuclei of hippocampal tissue of female and male rats in the 1800 MHz group were slightly contracted, the cytoplasm was slightly edema, and the nuclei of male rats were obviously irregular. In the offspring of male and female rats in the Wi-Fi group, the nucleus of hippocampal tissue contracted seriously, the cell membrane was irregular, and the cytoplasm appeared obvious edema. In the 1800 MHz+Wi-Fi group, the nuclei of hippocampal tissue of both male and female offspring rats were severely contracted, the nuclear membrane was irregular, and the cytoplasm was severely edema. there was no significant difference in FTO level among the groups ( P >0.05) . Compared with other groups, NGF content in hippocampus of offspring rats in the 1800 MHz+Wi-Fi group was significantly higher ( P <0.05) . Conclusion: Exposure to radio frequency electromagnetic fields will damage the morphological structure of hippocampal tissue of offspring and stimulate the increase of NGF expression in the hippocampus.
- Published
- 2022
- Full Text
- View/download PDF
19. [Histological regression and clinical benefits in patients with liver cirrhosis after long-term anti-HBV treatment].
- Author
-
Chen SY, Sun YM, Zhou JL, Wu XN, Meng TT, Wang BQ, Liu H, Wang TL, Shao C, Zhao XY, Xu XQ, Kong YY, Ou XJ, Jia JD, and You H
- Subjects
- Antiviral Agents therapeutic use, Hepatitis B virus genetics, Humans, Liver Cirrhosis pathology, Hepatitis B, Chronic complications, Liver pathology
- Abstract
Objective: Our study aims to determine histological regression and clinical improvement after long-term antiviral therapy in hepatitis B virus-related cirrhosis patients. Methods: Treatment-naïve chronic hepatitis B patients with histologically or clinically diagnosed liver cirrhosis were enrolled. Liver biopsies were performed after 5 years entecavir-based antiviral treatment. Patients were followed up every 6 months. Cirrhosis regression was evaluated based on Metavir system and P-I-R score. Clinical improvement was evaluated before and after the long-term treatment. Kruskal Wallis test and Wilcoxon signed-rank test were used for continuous variables, Fisher's exact test was used for categorical variables and multivariate analysis was performed using logistic regression analysis. Results: Totals of 73 patients with HBV-related liver cirrhosis were enrolled. Among them, 30 (41.1%) patients were biopsy proved liver cirrhosis and the remaining 43 (58.9%) cirrhotic patients were diagnosed by clinical features. Based on Metavir system and P-I-R score, 72.6% (53/73) patients attained histological regression. Furthermore, 30.1% (22/73) were defined as significant regression (Metavir decrease ≥2 stage), 42.5% (31/73) were mild regression (Metavir decrease 1 stage or predominantly regressive by P-I-R system if still cirrhosis after treatment) and 27.4% (20/73) were the non-regression. Compared to levels of clinical characteristics at baseline, HBV DNA, ALT, AST, liver stiffness(decreased from 12.7 to 6.4 kPa in significant regression, from 18.1 to 7.3 kPa in mild regression and from 21.4 to 11.2 kPa in non-regression)and Ishak-HAI score significantly decreased after 5 years of anti-HBV treatment, while serum levels of platelets and albumin improved remarkably ( P <0.05). In multivariate analysis, only the pre-treatment liver stiffness level was associated with significant regression ( OR =0.887, 95% CI : 0.802-0.981, P =0.020). Conclusions: After long-term antiviral therapy, patients with HBV-related cirrhosis are easily to attain improvements in clinical parameters, while a certain percentage of these patients still cannot achieve histological reversal.
- Published
- 2022
- Full Text
- View/download PDF
20. [Analysis of change in esophageal varices and clinical characteristics in hepatitis B virus-related cirrhosis after antiviral therapy].
- Author
-
Wang BQ, Wu XN, Zhou JL, Sun YM, Meng TT, Chen SY, Guan QS, He ZY, Wu SS, Kong YY, Ou XJ, Jia JD, and You H
- Subjects
- Antiviral Agents therapeutic use, Hepatitis B virus, Humans, Liver Cirrhosis diagnosis, Prospective Studies, Esophageal and Gastric Varices drug therapy, Esophageal and Gastric Varices etiology, Varicose Veins
- Abstract
Objective: To clarify the effect and related factors of antiviral therapy on the change of esophageal varices in patients with hepatitis B virus-related cirrhosis. Methods: Fifty-two cases with hepatitis B virus-related cirrhosis who underwent endoscopy before and after antiviral therapy were selected from prospective cohorts. Patients were divided into three groups: no, mild, and moderate-severe based on the degree of esophageal varices. The changes in the severity of esophageal varices in each group were compared after antiviral therapy. Clinical characteristics (platelet, liver and kidney function, liver stiffness, and virological response) of patients with different regressions were analyzed. Measurement data were analyzed by independent sample t-test, one-way ANOVA, Mann-Whitney U test and Kruskal-Wallis H test, and Chi-Square test was used for count data. Results: All patients received entecavir-based antiviral therapy. The median treatment time was 3.1 (2.5-4.4) years. The proportion of patients without esophageal varices increased from 30.8% to 51.9%, the proportion of mild esophageal varices decreased from 40.4% to 30.8%, and the proportion of patients with moderate-to-severe esophageal varices decreased from 28.8% to 17.3% ( χ
2 =14.067, P =0.001). A total of 40.4% of patients had esophageal varices regression, and 13.5% had esophageal varices progression. The progression rate was significantly higher in patients with moderate-severe esophageal varices than patients with mild and no esophageal varices ( χ2 =28.126, P <0.001), and 60.0% of patients with moderate-severe esophageal varices still remained in moderate-severe state after antiviral treatment. Baseline platelet count and 5-year mean change rates were significantly lower in patients with progressive moderate-to-severe esophageal varices than in those without progression (+3.3% vs . +34.1%, Z =7.00, P =0.027). Conclusion: After effective antiviral treatment, 40.4% of patients with hepatitis B virus-related cirrhosis combined with esophageal varices has obtained esophageal varices regression, but those with moderate to severe esophageal varices still have a considerable risk of progression while receiving mono antiviral treatment only. Thrombocytopenia and without significant improving are the clinical signs of progression risk after receiving antiviral treatment.- Published
- 2022
- Full Text
- View/download PDF
21. [Etiological and epidemiological characteristics of Vibrio cholerae in Beijing, 2015-2021].
- Author
-
Huang Y, Jia L, Tian Y, Lyu B, Qu M, Zhang X, Liu BW, Huo D, Wu XN, Yan HQ, and Yang P
- Subjects
- Adult, Beijing epidemiology, Diarrhea epidemiology, Electrophoresis, Gel, Pulsed-Field, Humans, Middle Aged, Young Adult, Cholera drug therapy, Cholera epidemiology, Vibrio cholerae O1 genetics
- Abstract
Objective: To analyze the etiological and epidemiological characteristics of Vibrio cholerae in Beijing during 2015-2021 and provide evidence for the prevention and control of cholera. Methods: The V. cholerae strains isolated in Beijing during 2015-2021 were analyzed by serotyping and virulence genes detection. Pulsed field gel electrophoresis (PFGE) was performed for the molecular typing of the strains. Based on the collected epidemiological and clinical data of cholera cases,the epidemiological characteristics of cholera were analyzed by descriptive epidemiology method. Results: A total of 76 Vibrio cholerae O1 strains were isolated in Beijing during 2015-2021, including 61 strains from human, 10 strains from environment and 5 strains from seafood. The 76 strains consisted of 68 Ogawa strains and 8 Inaba strains. Six Ogawa strains isolated from sporadic cases carried ctxAB . After Not Ⅰ digestion, 76 strains were divided into 33 PFGE patterns. From 2015 to 2021, a total of 38 cholera epidemics were reported in Beijing, most of them were sporadic ones, accounting for 92.11% (35/38). A total of 45 cases were reported, and the cases occurred during June-September accounted for 97.78% (44/45). Cholera cases occurred in 9 districts of Beijing, and the cases reported in Chaoyang district accounted for 42.22% (19/45) and in Changping district accounted for 31.11% (14/45). The age of the cholera cases ranged from 19 to 63 years. Except for one case with unknown clinical symptoms, 44 cases had diarrhea symptoms with 84.09% (37/44) of the cases reporting diarrhea (3-9 times/day), followed by yellow watery stool (95.45%, 42/44), abdominal pain (68.18%, 30/44), nausea and vomiting (40.91%, 18/44) and fever (36.36%, 16/44). Conclusion: Vibrio cholerae strains isolated in Beijing during 2015-2021 were mainly O1 serotype Ogawa,most of which were non-toxigenic. The PFGE of the strains varied. Cholera epidemics occurred in 9 districts of Beijing, but most were sporadic ones with incidence peak during June-September.
- Published
- 2022
- Full Text
- View/download PDF
22. [Characteristics of heart rate variability in patients with vestibular migraine].
- Author
-
Zhao YM, Liu CL, Li YL, Jia J, Wu XN, Li SN, Sun LT, and Nie L
- Subjects
- Adult, Female, Heart Rate physiology, Humans, Male, Middle Aged, Migraine Disorders, Vertigo
- Abstract
Objective: To analyze the characteristics of heart rate variability (HRV) in patients with vestibular migraine (VM) and to explore its possible mechanism. Methods: Forty-eight patients with VM [17 males and 31 females, age (36.2±9.2) years], 44 patients with migraine [15 males and 29 females, age (34.4±9.0) years], and 30 patients with health check-ups during the same period [12 males and 18 females, age (34.6±6.5) years old] were selected as study subjects. Ambulatory ECG monitoring was performed in all subjects, and the HRV characteristics of each group were analyzed from both daytime and nighttime time phases. Time domain parameters were analyzed: standard deviation of normal to normal (SDNN), root mean square of successive differences (RMSSD), and percentage of normal to normal intervals differing by more than 50 ms (pNN50). The parameters in the frequency domain were analyzed: high frequency power (HF), low frequency power (LF), and the ratio of low frequency to high frequency power (LF/HF). Statistical analysis of the data was performed using SPSS 26.0 software. Results: At night, RMSSD ( F =6.694) and HF ( F =9.434) were lower in the VM and migraine groups compared to the control group, while LF/HF ( F =16.049) and LF ( F =9.434) were elevated compared to the control group, with statistically significant differences ( P <0.05 or P <0.01), while LF was significantly elevated in the VM group compared to the migraine group, with a statistically significant ( P <0.05). On the daytime measurements, mainly LF was elevated in the vestibular migraine group compared with the control group, while RMSSD was decreased compared with the control group, with statistically significant differences ( P <0.05). Conclusion: Autonomic dysfunction characterized by sympathetic hyperfunction and vagal hypofunction is present in VM patients and is more pronounced at night. In addition, the degree of autonomic dysfunction may be more pronounced in VM patients than in migraine patients.
- Published
- 2022
- Full Text
- View/download PDF
23. [Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study].
- Author
-
Zhang XF, Liu Y, Li JH, Lei P, Zhang XY, Wan Z, Lei T, Zhang N, Wu XN, Long ZD, Li ZF, Wang B, Liu XM, Wu Z, Chen X, Wang JX, Yuan P, Li Y, Zhou J, Pawlik M, and Lyu Y
- Subjects
- Cohort Studies, Humans, Liver Cirrhosis complications, Splenectomy, Carcinoma, Hepatocellular, Hypertension, Portal complications, Liver Neoplasms surgery
- Abstract
Objective: To identify whether splenectomy for treatment of hypersplenism has any impact on development of hepatocellular carcinoma(HCC) among patients with liver cirrhosis and hepatitis. Methods: Patients who underwent splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension between January 2008 and December 2012 were included from seven hospitals in China, whereas patients receiving medication treatments for liver cirrhosis and portal hypertension (non-splenectomy) at the same time period among the seven hospitals were included as control groups. In the splenectomy group, all the patients received open or laparoscopic splenectomy with or without pericardial devascularization. In contrast, patients in the control group were treated conservatively for liver cirrhosis and portal hypertension with medicines (non-splenectomy) with no invasive treatments, such as transjugular intrahepatic portosystemic shunt, splenectomy or liver transplantation before HCC development. All the patients were routinely screened for HCC development with abdominal ultrasound, liver function and alpha-fetoprotein every 3 to 6 months. To minimize the selection bias, propensity score matching (PSM) was used to match the baseline data of patients among splenectomy versus non-splenectomy groups. The Kaplan-Meier method was used to calculate the overall survival and cumulative incidence of HCC development, and the Log-rank test was used to compare the survival or disease rates between the two groups. Univariate and Cox proportional hazard regression models were used to analyze the potential risk factors associated with development of HCC. Results: A total of 871 patients with liver cirrhosis and hypertension were included synchronously from 7 tertiary hospitals. Among them, 407 patients had a history of splenectomy for hypersplenism (splenectomy group), whereas 464 patients who received medical treatment but not splenectomy (non-splenectomy group). After PSM,233 pairs of patients were matched in adjusted cohorts. The cumulative incidence of HCC diagnosis at 1,3,5 and 7 years were 1%,6%,7% and 15% in the splenectomy group, which was significantly lower than 1%,6%,15% and 23% in the non-splenectomy group ( HR =0.53,95% CI :0.31 to 0.91, P =0.028). On multivariable analysis, splenectomy was independently associated with decreased risk of HCC development ( HR =0.55, 95%CI: 0.32 to 0.95, P =0.031). The cumulative survival rates of all the patients at 1,3,5,and 7 years were 100%,97%,91%,86% in the splenectomy group,which was similar with that of 100%,97%,92%,84% in the non-splenectomy group ( P =0.899). In total,49 patients (12.0%) among splenectomy group and 75 patients (16.2%) in non-splenectomy group developed HCC during the study period, respectively. Compared to patients in non-splenectomy group, patients who developed HCC after splenectomy were unlikely to receive curative resection for HCC (12.2% vs. 33.3%,χ²=7.029, P =0.008). Conclusion: Splenectomy for treatment of hypersplenism may decrease the risk of HCC development among patients with liver cirrhosis and portal hypertension.
- Published
- 2021
- Full Text
- View/download PDF
24. Inhibition of microRNA-184 reduces H2O2-mediated cardiomyocyte injury via targeting FBXO28.
- Author
-
Zou JF, Wu XN, Shi RH, Sun YQ, Qin FJ, and Yang YM
- Subjects
- Animals, Apoptosis, Cell Survival, Cells, Cultured, Hydrogen Peroxide antagonists & inhibitors, Hydrogen Peroxide pharmacology, MicroRNAs genetics, Myocytes, Cardiac drug effects, Myocytes, Cardiac pathology, Rats, MicroRNAs metabolism, Myocytes, Cardiac metabolism, SKP Cullin F-Box Protein Ligases metabolism
- Abstract
Objective: Cardiovascular disease, especially coronary heart disease, is one of the diseases with the highest mortality. A large number of studies have found that microRNAs (miRNAs) are closely related to the occurrence and development of myocardial ischemia. This article mainly focused on the regulation of miR-184 on oxidative stress, inflammation, and apoptosis in myocardial infarction (MI)., Materials and Methods: MiR-184 inhibitor or negative control (NC) were transfected into H9c2 cells. Then, H9c2 cells were treated with H2O2 to construct a cardiomyocyte injury model. H9c2 cells were divided into 4 groups: control group, H22O2 treatment group, H2O2 + NC group, and H2O2 + miR-184 inhibitor group. The oxidative stress of H9c2 cells was observed by the expression levels of SOD, ROS, and MDA in each group. The inflammatory response of H9c2 cells was reflected by the expression of TNF-α, IL-6, and IL-1β detected by ELISA kits. Western blot was used to detect the expression of cleaved Caspase-3, Bcl-2, Bax and F-box protein 28 (FBXO28). Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was utilized to detect miR-184 expression. TdT-mediated dUTP Nick-End Labeling (TUNEL) staining and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay were used to observe the apoptosis and cell viability. The Luciferase reporter experiment was used to prove whether miR-184 could target FBXO28., Results: MiR-184 expression was significantly increased in H2O2-induced H9c2 cell injury model. After H9c2 cells were transfected with miR-184 inhibitor to silence miR-184, the levels of ROS and MDA were markedly reduced, while the expression of SOD was greatly increased. At the same time, the expression of inflammatory factors was greatly reduced. Silencing miR-184 also increased Bcl-2 expression, and reduced the expression of cleaved Caspase-3 and Bax. In addition, compared with the H2O2 + NC group, the number of TUNEL positive cells in the H2O2 + miR-184 inhibitor group was also significantly reduced, and the cell viability was remarkably increased. The Luciferase reporter experiment proved that FBXO28 is a target gene of miR-184., Conclusions: MiR-184 expression was increased in H2O2-treated H9c2 cells. Inhibition of miR-184 markedly inhibited oxidative stress and inflammation in cardiomyocytes, thereby inhibiting cardiomyocyte apoptosis, through the regulation of FBXO28.
- Published
- 2020
- Full Text
- View/download PDF
25. [Systematic evaluation of clinical trial protocols of new drugs as a cure of chronic hepatitis B].
- Author
-
Chen S, Zhao LH, Shan S, Li M, Sun YM, Zhou JL, Wu XN, Dong RH, Kong YY, Ou XJ, Ma H, You H, and Jia JD
- Subjects
- Humans, Research Design, Clinical Trials as Topic, Hepatitis B, Chronic drug therapy
- Abstract
Objective: To describe the current status of registration and design characteristics of clinical trials of new drugs for curing hepatitis B through domestic and foreign websites, so as to provide references for the follow-up clinical trials of new hepatitis B drugs. Methods: A search was conducted on the US Clinical Trials Database and the Chinese Clinical Trial Registry Center. The search date was from the establishment of the database to May 26, 2020, and the registration trials of new drugs for curing hepatitis B at home and abroad were included. Two researchers independently searched and screened the literature and extracted the data. Results: A total of 106 registered clinical trials of new drugs for curing hepatitis B were included (94 English registration websites and 12 Chinese registration websites), and the number of registrations had increased year by year. Among them, the proportion of therapeutic vaccines and core protein inhibitors were the highest, accounting for 27.4% ( n = 29) and 22.6% ( n = 24), respectively. The vast majority of clinical trials ( n = 96, 90.6%) were in the early stages (Phase I and II). The subjects in phase I clinical trial were mainly healthy people and treated CHB patients, while the subjects in phase II clinical trial were mainly CHB patients who had achieved viral suppression after initial or post-treatment. The main evaluation indicators of Phase I clinical trials were the safety and tolerability of new drugs. The main evaluation indicators in about half of Phase II clinical trials were HBsAg negative conversion/quantitative decline. Overall, the number of clinical trials with the new design was small, accounting for 3.8% (4 / 106). There were relatively few trials of new drugs for curing hepatitis B on domestic registration websites, and the information provided was incomplete. Conclusion: The number of clinical trials of new hepatitis B drugs at home and abroad is increasing year by year, but most of them are in phase I and II, with few adopting new designs. In addition, the information integrity of the domestic website registration center needs to be improved.
- Published
- 2020
- Full Text
- View/download PDF
26. [Phenotype and mechanism of inducible ppp2r1a knockout mouse model].
- Author
-
Fan JL, Wang FP, Wang S, Liu XL, Wu XN, Chen W, Chen LP, and Li WX
- Subjects
- Alanine Transaminase, Animals, Aspartate Aminotransferases, Cholesterol, Kidney, Lipid Metabolism, Liver, Lung, Lymphocyte Count, Mice, Spleen, Mice, Knockout, Phenotype, Protein Phosphatase 2 genetics
- Abstract
Objective: Investigate the effects of inducible ppp2r1a knockout on main physiological function in adult mice and study the mechanism. Methods: Ppp2r1a(flox/flox) mice and CAGG-CreER mice were hybridized to obtain 20 CAGG-CreER ppp2r1a(flox/flox) and 20 mice in homozygous group. Two groups of mice were divided into 4 groups respectively, finally we got 8 groups with 5 mice in each group. Tamoxifen was injected intraperitoneally to acquire inducible ppp2r1a knockout mice. The knockout efficiency of PP2A Aα in vital organs was measured by Western blot. At 0, 2, 4 and 6 days after injection, we measured body weight, histopathological change, peripheral blood cell counts and blood biochemical. Real-time PCR was performed to measure expression of liver glucolipid metabolism genes. Results: After tamoxifen injection for 6 days, the knockout efficiency of PP2A Aα in vital organs was 35%, 12%, 15%, 60%, 69% and 72%, respectively in heart, liver, spleen, lung, kidney and brain. After tamoxifen injection for 6 days, the weight of homozygous mice was lower than that of wild type mice, with values of (17.42±1.76) g and (21.69±1.82) g, respectively ( P< 0.05). Moreover, the activity level, abdominal and renal fat were significantly decreased in homozygous mice. Homozygous mice survived no more than 7 days. Compared with wild type mice, the organ coefficient of spleen of homozygous mice was decreased at the 6th day, with values of (0.59±0.10)% and (0.36±0.05)% respectively ( P< 0.05). Obvious spleen atrophy and marked decrease of nucleated cells were showed by performing HE staining. Tunel staining revealed increased apoptosis ratio of splenic lymphocytes in homozygous mice. The levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) of homozygous mice were higher than wild type mice ( P< 0.05). The values of ALT and AST in homozygous mice were (153.68±62.80) U/L and (193.2±44.28) U/L. The corresponding values in wild type mice were (41.02±12.91) U/L and (69.40±9.55) U/L. The above results indicated that ppp2r1a knockout caused liver damage. Blood sugar level of homozygous mice was lower than in wild type mice ( P< 0.05), with values of (4.20±1.99) mmol/L and (8.88±0.65) mmol/L respectively. Plasma total cholesterol (TC), high density lipoprotein (HDL) and β-hydroxybutyric acid (β-HB) level of homozygous mice were higher than those of wild type mice ( P< 0.05). The values of TC, HDL and β-HB in homozygous mice were (3.12±0.39), (1.53±0.38) and (2.49±0.89) mmol/L. The corresponding values in wild type mice were (1.69±0.92), (0.78±0.50) and (0.45±0.30) mmol/L respectively. The above results indicated that ppp2r1a loss interfered glucose and cholesterol metabolism. In addition, we also found that the white blood cell count (WBC) and lymphocyte count (LYM) of homozygous mice were lower than in wild type mice ( P< 0.05). The values of WBC and LYM in homozygous mice were (1.88±0.89)×10(9)/L and (0.92±0.37)×10(9)/L respectively. The corresponding values in wild type mice were (3.91±0.80)×10(9)/L and (2.74±0.52)×10(9)/L respectively. The mRNA levels of glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinase (PEPCK) of homozygous were lower than wild type mice ( P< 0.05). The fold change of G6P and PEPCK in homozygous mice was 0.46±0.11 and 0.72±0.07 respectively. The corresponding fold change in wild type mice was 1.02±0.07 and 1.02±0.06 respectively. Conclusion: Whole body ppp2r1a is essential for the survival of adult mice, due to the important role in maintaining the metabolism of glucose and cholesterol of liver.
- Published
- 2018
- Full Text
- View/download PDF
27. [Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
- Author
-
Sun YM, Zhou JL, Wang L, Wu XN, Chen YP, Piao HX, Lu LG, Jiang W, Xu YQ, Feng B, Nan YM, Xie W, Chen GF, Zheng HW, Li H, Ding HG, Liu H, Lyu FD, Shao C, Wang TL, Ou XJ, Wang BQ, Chen SY, You H, and Jia JD
- Subjects
- Alanine Transaminase blood, Antiviral Agents therapeutic use, Hepatitis B, Chronic complications, Hepatitis B, Chronic drug therapy, Humans, Liver Cirrhosis drug therapy, Hepatitis B, Chronic pathology, Liver pathology, Liver Cirrhosis pathology
- Abstract
Objective: To investigate the methods for qualitative pathological assessment of dynamic changes in liver fibrosis/cirrhosis after antiviral therapy in patients with chronic hepatitis B (CHB), since antiviral therapy can partially reverse liver fibrosis and cirrhosis caused by hepatitis B and semi-quantitative, rather than qualitative, pathological assessment is often used for the research on liver fibrosis regression. Methods: Previously untreated CHB patients with liver fibrosis and cirrhosis were enrolled, and liver biopsy was performed before treatment and at 78 weeks after the antiviral therapy based on entecavir. The follow-up assessment was performed once every half a year. Based on the proportion of different types of fibrous septum, we put forward the new qualitative criteria called P-I-R classification (predominantly progressive, predominantly regressive, and indeterminate) for evaluating dynamic changes in liver fibrosis. This classification or Ishak fibrosis stage was used to evaluate the change in liver fibrosis after treatment and Ishak liver inflammation score was used to evaluate the change in liver inflammation after treatment. Results: A total of 112 CHB patients who underwent liver biopsy before and after treatment were enrolled, and among these patients, 71 with an Ishak stage of ≥3 and qualified results of live biopsy were included in the final analysis. Based on the P-I-R classification, 58% (41/71) were classified as predominantly progressive, 29% (21/71) were classified as indeterminate, and 13% (9/71) were classified as predominantly regressive; there were no significant differences between the three groups in alanine aminotransferase, aspartate aminotransferase, albumin, HBeAg positive rate, HBV DNA, and liver stiffness ( P < 0.05). After treatment, the proportion of predominantly progressive, indeterminate, or predominantly regressive patients changed to 11% (8/71), 11% (8/71), and 78% (55/71), respectively. Among the 35 patients who had no change in Ishak stage after treatment, 72% (25/35) were classified as predominantly regressive and had certain reductions in the Laennec score, percentage of collagen area, and liver stiffness. Conclusion: This new P-I-R classification can be used to assess the dynamic changes in liver fibrosis after antiviral therapy in CHB patients.
- Published
- 2017
- Full Text
- View/download PDF
28. [Prognostic analysis of patients with myasthenia gravis after extended thymectomy].
- Author
-
Li T, Wu XN, Xie MR, Mei XY, Zhang WJ, and Ma DC
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Preoperative Period, Prognosis, Regression Analysis, Retrospective Studies, Steroids, Treatment Outcome, Young Adult, Myasthenia Gravis surgery, Thymectomy
- Abstract
Objective: To identify the long-term outcome of patients with myasthenia gravis (MG) after extended thymectomy, and to analyze the prognostic factors. Methods: The medical data and follow-up results in 72 patients with MG who underwent extended thymectomy in Department of Thoracic Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University from January 2006 to October 2015 were retrospectively reviewed and analyzed. There were 32 male and 40 female patients, aging from 10 to 70 years with a mean age of 39.5 years. The outcome-related factors including gender, age while being operated on, duration of preoperative period, whether taking steroid before operation, modified Osserman classification, pathology type of thymus were analyzed by χ(2) test and multivariate regression analysis. Results: All patients were followed up from 6 to 75 months (median 37 months). Among them, 21 patients (29.2%) achieved complete stable remission, 18 patients (25.0%) experienced pharmacological remission, 20 patients (27.8%) improved, 9 patients (12.5%) reminded stable and 4 patients (5.6%) deteriorated. Both univariate and multicariate analysis revealed that duration of preoperative period ( OR =22.871, 95% CI: 2.813 to 185.917, P =0.003) and Osserman classification ( OR =0.103, 95% CI: 0.014 to 0.774, P =0.027) showed significantly associated with the surgical curative effect. Conclusions: Extended thymectomy is an efective measure for MG. The duration of preoperative period and Osserman classification are prognostic factors for thymectomized MG. Those patients with generalized MG or whose duration of preperative period is less than 6 months are likely to have better prognosis.
- Published
- 2017
- Full Text
- View/download PDF
29. [A discussion of the methods for the assessment of chronic hepatitis B-related liver fibrosis regression].
- Author
-
Sun YM, Wu XN, Zhou JL, and You H
- Subjects
- Biomarkers blood, Biopsy, Humans, Liver Cirrhosis pathology, Hepatitis B, Chronic pathology, Liver Cirrhosis diagnosis
- Abstract
Antiviral therapy could reverse hepatitis B-related liver fibrosis and early-stage cirrhosis. However, the assessment of fibrosis regression remains controversial. As the gold standard for assessment, liver biopsy has its own limitations. In terms of non-invasive assessment, there are many interfering factors for transient elastography and less clinical evidence for the use of serum markers. Therefore, further evidence from clinical studies is still needed to determine the role of non-invasive methods in evaluating fibrosis regression.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.